Safety of Hormone Replacement Therapy (HRT) in Systemic Lupus Erythematosus (SLE)

Abstract

Despite its obvious benefits, many physicians are reluctant to prescribe HRT to patients with SLE. We have performed a retrospective study in 60 postmenopausal women with SLE including 30 HRT users and 30 never users. The patients were studied for 12 months after the initiation of HRT. The two groups were well matched for disease characteristics. The HRT users experienced significant improvements in general well being, libido and depression. There was no significant difference in any other parameter measured. There was no increase in the number of thrombo-embolic events in the user group despite 7 patients having a positive thrombophilia screen. In conclusion, in stable postmenopausal SLE HRT appears well tolerated and safe.

Keywords

Systemic lupus erythematosus Hormone replacement therapy Thromboembolic events

Get full access to this article

View all access options for this article.

References

Riggs BL , Melton LJ The prevention and treatment of osteoporosis. New Engl J Med 1992; 327: 620-7.

Hall GM , Daniels M. , Wiltshire P. , O'Gara C. , Spector TD The effects of oestrogen replacement therapy and calcium on bone loss in rheumatoid arthritis: a 2 year prospective study. Arthrit Rheum 1993; 36: S50 (abstract 72).

Stampfer MJ , Colditz GA , Willett WC et al. Postmenopausal estrogen therapy and cardiovascular disease. New Engl J Med 1991; 325: 756-62.

Petri M. , Perez-Gutthann S. , Spence D. , Hochberg MC Risk factors for coronary artery disease in patients with systemic lupus erythematosus . Am J Med 1992; 93: 513-19.

Jungers P. , Dougados M. , Pelissier C. et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 618-23.

Julkenen HA Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991; 20: 427-33.

Barrett C. , Neylon N. , Snaith M. Oestrogen-induced systemic lupus erythematosus. Br J Rheum 1986; 25: 300-1.

Lidegaard O. Oral contraception and the risk of cerebral thromboembolic attack: results of a case control study. Br Med J 1993; 306: 956-63.

Hughes Grv , Harris N. , Gharavi A. The anti-cardiolipin syndrome. J Rheum 1986 ; 13: 486-9.

10.

Ravnikar VA Compliance with hormone therapy. Am J Obstet Gynecol 1987; 1565: 1332-4.

11.

Devor M. , Barrett-Connor E. , Renvall M. , Feigal D. , Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-282.